Kamiya Kuniyoshi, Sugiyama Kumiya, Toda Masao, Soda Sayo, Ikeda Naoya, Fukushima Fumiya, Hirata Hirokuni, Fukushima Yasutsugu, Fukuda Takeshi
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Mibu, Tochigi 321-0293, Japan.
Asia Pac Allergy. 2012 Jan;2(1):49-58. doi: 10.5415/apallergy.2012.2.1.49. Epub 2012 Jan 31.
Exacerbation of asthma has a negative impact on quality of life and increases the risk of fatal asthma. One of the known risk factors for patients with a history of near-fatal asthma is reduced sensitivity to dyspnea.
We aimed to identify patients with such risk before they experienced severe exacerbation of asthma.
We analyzed asthma symptoms and peak expiratory flow rate (PEFR) values of 53 patients recorded daily in a diary over a mean period of 274 days. Patients matched their symptoms to one of eight categories ranging in severity from 'absent' to 'severe attack'. We then analyzed the relationship between PEFR and asthma symptoms by dividing the PEFR value by the values of clinical parameters, including asthma symptom level.
Average PEFR was 75.2% (50.5-100%) in the 'absent' symptom category, 64.5% (36.6-92.6%) in 'wheeze', 57.3% (25.0-94.7%) in 'mild attack' and 43.6% (20.4-83.1%) in 'moderate attack', with the personal best reading taken as 100%. Thus, differences in PEFR in patients in the same symptom category varied widely. PEFR in wheeze, mild attack and moderate attack did not correlate significantly with duration of asthma, forced expiratory volume in one second or proportion of personal best to standard predicted PEFR values. These PEFRs showed no significant difference in groups divided by type of regular treatment, but showed a significant negative correlation with the coefficient of variation (CV) of PEFR when asthma symptoms were absent. CV for absent symptoms should be between +4.0 and -4.0% when using regression analysis to measure PEFR if the decreased PEFR is in agreement with guidelines.
To determine which patients have reduced sensitivity to dyspnea, CV of PEFR should be considered when asthma symptoms are reported as absent. When patients present with more than 8% fluctuation in PEFR, we should intervene in their treatment, even when they claim to be stable.
哮喘急性发作会对生活质量产生负面影响,并增加致死性哮喘的风险。已知的近致死性哮喘病史患者的风险因素之一是对呼吸困难的敏感性降低。
我们旨在在患者经历哮喘严重急性发作之前识别出有此类风险的患者。
我们分析了53例患者在平均274天的时间里每日记录在日记中的哮喘症状和呼气峰值流速(PEFR)值。患者将其症状与从“无”到“严重发作”的八个严重程度类别之一进行匹配。然后,我们通过将PEFR值除以包括哮喘症状水平在内的临床参数值,分析了PEFR与哮喘症状之间的关系。
在“无”症状类别中,平均PEFR为75.2%(50.5 - 100%),“喘息”时为64.5%(36.6 - 92.6%),“轻度发作”时为57.3%(25.0 - 94.7%),“中度发作”时为43.6%(20.4 - 83.1%),个人最佳读数设为100%。因此,同一症状类别患者的PEFR差异很大。喘息、轻度发作和中度发作时的PEFR与哮喘病程、一秒用力呼气量或个人最佳值与标准预测PEFR值的比例均无显著相关性。这些PEFR在按常规治疗类型划分的组中无显著差异,但在哮喘症状不存在时与PEFR的变异系数(CV)呈显著负相关。如果使用回归分析测量PEFR时PEFR降低符合指南,无症状时的CV应在 +4.0%至 -4.0%之间。
为了确定哪些患者对呼吸困难的敏感性降低,当报告哮喘症状不存在时,应考虑PEFR的CV。当患者的PEFR波动超过8%时,即使他们声称病情稳定,我们也应干预其治疗。